241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 241,966 shares of the biotechnology company's stock, valued at approximately $21,104,000. Raymond James Financial Inc. owned 0.38% of Blueprint Medicines as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BPMC. Vanguard Group Inc. increased its holdings in shares of Blueprint Medicines by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after buying an additional 91,450 shares during the last quarter. Wellington Management Group LLP increased its stake in Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after acquiring an additional 316,754 shares during the last quarter. William Blair Investment Management LLC raised its position in Blueprint Medicines by 16.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock valued at $169,616,000 after purchasing an additional 269,896 shares during the period. Geode Capital Management LLC lifted its stake in shares of Blueprint Medicines by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock valued at $129,996,000 after purchasing an additional 9,914 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in shares of Blueprint Medicines by 1.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,183,682 shares of the biotechnology company's stock worth $103,241,000 after purchasing an additional 17,175 shares during the period.

Blueprint Medicines Stock Up 0.7 %

BPMC traded up $0.59 on Thursday, reaching $86.40. The company's stock had a trading volume of 72,936 shares, compared to its average volume of 766,688. The company has a market capitalization of $5.52 billion, a price-to-earnings ratio of -79.99 and a beta of 0.75. Blueprint Medicines Co. has a fifty-two week low of $73.04 and a fifty-two week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The stock has a 50 day moving average of $87.82 and a two-hundred day moving average of $93.12.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. This represents a 3.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ariel Hurley sold 3,203 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have commented on BPMC. Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They issued a "buy" rating and a $135.00 target price on the stock. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They set an "outperform" rating for the company. Morgan Stanley began coverage on Blueprint Medicines in a research report on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Finally, Stephens reiterated an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.95.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.